Read this company snapshot
Daily valuation snapshot
Capricor Therapeutics Inc: source evidence dated 2026-10-09.
- Daily close (USD)
- $7.83
- Market capitalization (USD)
- $455,228,283.87
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.85
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CAPR in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CAPR in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing CAPR with another company.
| Daily close (USD) | $7.83 |
| Market capitalization (USD) | $455,228,283.87 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.85 |
No matching rows. Clear the filter to see all records.
Read CAPR's valuation metrics
Company size
Capricor Therapeutics Inc's recorded market capitalization is $455,228,283.87. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CAPR's recorded price-to-book ratio is 1.85. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Capricor Therapeutics Inc with Aurora
Use the snapshot above to ask a specific question about CAPR. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CAPR's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.